On 20th April Nic Puntis (Chair GSUK) & Jayne Bressington (Vice Chair GSUK / Patient Director PAWS-GIST, pictured left) went to Westminster and attended a parliamentary reception organised by Cancer52, a coalition of more than 80 charities representing rare and less common cancers. The reception was hosted and addressed by Chairman of the All-Party Parliamentary Group on Cancer […]
Continue reading
GIST News
GSUK Research Update – April 2016
In 2012 GIST Support UK granted £20,000 funding to Professor Ian Judson and his team at the Royal Marsden for a research project. This project aimed to collect tissue samples stored in hospital pathology departments for GIST patients who had been treated at the Marsden over previous years and then to retrospectively undertake mutational analysis of […]
Continue readingRide London 2016
We still have one place available. Go to our Fundraising page for more details.
Continue readingRegorafenib remains on the CDF in England for GIST patients – September 2015
As you may already be aware, great news was released on Friday 4th September that Regorafenib has remained on the NHS England Cancer Drug Fund List for GIST patients, having stayed above the threshold for inclusion on the CDF, further to the second phase of review. At the patient organisation briefing in Whitehall this morning, […]
Continue readingPAWS-GIST – Clinic 5 – August 2015
Click here to read about the latest clinic news…
Continue readingRegorafenib recommended for use within NHS Wales for GIST – July 2015
We are delighted to report that Regorafenib has been recommended for use within NHS Wales for GIST Please see the AWMSG Website. This means that within three months of Ministerial approval (issued July 2015), regorafenib will be routinely available in the NHS across Wales. A fantastic outcome for GIST patients in Wales!
Continue reading#100,000voices e-petition delivered to No. 10 Downing Street – 23 June 2015
Sincere thanks to everyone who has supported us with the call to retain regorafenib on the Cancer Drugs fund for GIST patients. Yesterday was our appointment with No. 10 Downing Street to deliver our #100,000voices e-petition containing 103,841 signatures supporting retention of regorafenib for GIST patients in England. We were joined by MP’s representing constituents […]
Continue readingRegorafenib is now officially back on the cancer drugs fund for GIST patients in England – 2015
23rd May 2015 – We are absolutely delighted to report that Regorafenib is now officially back on the cancer drugs fund for GIST patients in England. This is fantastic news and we would like to thank everyone who contributed to this decision: our fantastic #100,000voices team including William Bassett and the team at TMW. our Clinicians […]
Continue readingregorafenib (Stivarga®) is accepted for use within NHS Scotland – 2015
regorafenib has been approved in Scotland for treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who have progressed on or are intolerant to prior treatment with imatinib and sunitinib. This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of regorafenib and is contingent […]
Continue readingGIST Support UK’s #100000voices Campaign 2015
March 2015 Jayne Bressington, vice chair of GIST Support UK (https://www.gistcancer.org.uk/), talks to BBC Radio Humberside about the government’s plans to stop funding for the rare cancer drug Regorafenib. The petition to stop these cuts has gained 100,000+ signatures and we are now calling on everyone to write to their local parliamentary candidates ahead of […]
Continue reading